- Series: NSCLC
- Expires: November 28, 2023
- Credit: 0.30hr(s)
- NCPD
- Therapeutic Areas: Hematologic Oncology, Oncology
- Specialties: Biomarkers, NSCLC
Despite advances with targeted therapies, adverse events (AEs) must be identified and managed for optimal treatment response, clinical outcomes, and quality of life for patients with non-small cell lung cancer (NSCLC). Join us for the final episode of the 4-part educational initiative Biomarker-based Therapy for NSCLC: Improving Collaboration, Communication, and Care, in which our expert faculty have a candid conversation about mitigating common AEs associated with targeted therapies and provide strategies for engaging underserved patients in the prevention and monitoring of these potential toxicities.